Chromogranin A in the Follow-up of Digestive Neuroendocrine Neoplasms: Is It a Useful Biomarker? Abstract #1533

Introduction: Chromogranin A (CgA) is the most frequently used biomarker in digestive neuroendocrine neoplasms (DNENs) but its real usefulness is still unclear
Aim(s): To identify CgA clinical usefulness and the most accurate cut-off to detect disease progression (DP) or recurrence (DR) in the follow-up of DNEN
Materials and methods: Unicenter retrospective analysis of sporadic DNENs with ≥ 24-mos follow-up and ≥2 CgA assessments. Circulating CgA was measured by Cisbio CgA-RIA (Gif-sur-Yvette, France). For clinical usefulness we meant CgA accuracy in detecting DP/DR at least 3 mos before imaging tests, and considered only cases in which CgA was measured before DP/DR. We analyzed CgA accuracy using different CgA changes: increase ≥50% from previous CgA level, increase ≥ 30%, ≥ 2xULN
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: MD, PhD Elettra Merola

To read results and conclusion, please login ...

Further abstracts you may be interested in

#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel
#436 Role of Somatostatin Analogues in the Management of Merkel Cell Carcinoma: A Case Report
Introduction: Merkel cell carcinoma (MCC) is a relatively rare neuroendocrine malignant tumor that is characterized by an aggressive course with regional nodal involvement, distant metastases and a high rate of recurrence.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Kristina Orlova
#498 Limitations of Chromogranin A in Clinical Practice
Introduction: Chromogranin-A (CgA) is the most accurate marker for the histological diagnosis of neuroendocrine tumors (NETs). However diagnostic usefulness of circulating CgA is controversial as several conditions, both neoplastic and non-neoplastic, may induce false positive increases of this marker.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Vincenzo Marotta
#661 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Carcinoid Syndrome: Results of a Phase 2, Multicenter, Open-label, Serial-Ascending Study
Introduction: Excess serotonin (5-HT) in patients (pts) with carcinoid syndrome (CS) is associated with symptoms including increased bowel movement (BM) frequency.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#642 Correlation Between Chromogranin A and RECIST in Neuroendocrine Tumors’ Treatment
Introduction: High Chromogranin A (CGA) levels have been associated with both tumor burden and the secretory activity of GEPNETs specially carcinoids.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: PhD MD Paula Jimenez Fonseca
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.